Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer

被引：0

作者：

Edurne Arriola

Socorro Maria Rodriguez-Pinilla

Maryou B. K. Lambros

Robin L. Jones

Michelle James

Kay Savage

Ian E. Smith

Mitch Dowsett

Jorge S. Reis-Filho

机构：

[1] Institute of Cancer Research,The Breakthrough Breast Cancer Research Centre

[2] Royal Marsden Hospital,Department of Academic Biochemistry

[3] Royal Marsden Hospital,Breast Unit

来源：

Breast Cancer Research and Treatment | 2007年 / 106卷

关键词：

Anthracyclines; Breast cancer; Chromogenic ; hubridisation; HER2; Topoisomerase II alpha;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：181 / 189

页数：8

共 50 条

[41] Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer
Lauterlein, Jens-Jacob L.
Petersen, Eva R. B.
Olsen, Dorte Aa
Ostergaard, Birthe
Brandslund, Ivan
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) : 877 - 883
[42] Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013
Harris, Lyndsay N.
Broadwater, Gloria
Abu-Khalaf, Maysa
Cowan, David
Thor, Ann D.
Budman, Daniel
Cirrincione, Constance T.
Berry, Donald A.
Winer, Eric P.
Hudis, Clifford A.
Hayes, Daniel F.
Friedman, Paula
Ellis, Matthew
Dressler, Lynn
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3430 - 3436
[43] Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
Advani, Pooja
Cornell, Lauren
Chumsri, Saranya
Moreno-Aspitia, Alvaro
BREAST CANCER-TARGETS AND THERAPY, 2015, 7 : 321 - 335
[44] Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
O'Malley, F. P.
Chia, S.
Tu, D.
Shepherd, L. E.
Levine, M. N.
Bramwell, V. H.
Andrulis, I. L.
Pritchard, K. I.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (09): : 644 - 650
[45] HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344.
Hayes, D. F.
Thor, A.
Dressler, L.
Weaver, D.
Broadwater, G.
Goldstein, L.
Martino, S.
Ingle, J.
Henderson, I. C.
Berry, D.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 5S - 5S
[46] Amplification of HER-2/neu and Topoisomerase IIα in primary and metastatic breast cancer
Tanner, M
Järvinen, P
Isola, J
CANCER RESEARCH, 2001, 61 (14) : 5345 - 5348
[47] Topoisomerase II-alpha (TOP2A) gene co-amplification does not predict response to therapy and survival in Her-2 neu positive metastatic breast cancer
Kapoor, A.
Chow, S.
Bhargava, R.
Surti, U.
Rosenzweig, M.
Vuga, M.
Brufsky, A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[48] HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab
Ithimakin, Suthinee
Day, Kathleen C.
Malik, Fayaz
Zen, Qin
Dawsey, Scott J.
Bersano-Begey, Tom F.
Quraishi, Ahmed A.
Ignatoski, Kathleen Woods
Daignault, Stephanie
Davis, April
Hall, Christopher L.
Palanisamy, Nallasivam
Heath, Amber N.
Tawakkol, Nader
Luther, Tahra K.
Clouthier, Shawn G.
Chadwick, Whitney A.
Day, Mark L.
Kleer, Celina G.
Thomas, Dafydd G.
Hayes, Daniel F.
Korkaya, Hasan
Wicha, Max S.
CANCER RESEARCH, 2013, 73 (05) : 1635 - 1645
[49] HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab
Maiik, Fayaz
Ithimakin, Suthinee
Day, Kathleen
Ignatoski, Kathy
Zen, Qin
Thomas, Dafydd
Bersano, Tom
Dawsey, Scott
Hall, Christopher
Davis, April
Quraishi, Ahmed A.
Tawakkol, Nader
Clouthier, Shawn G.
Day, Mark
Hayes, Daniel F.
Korkaya, Hasan
Wicha, Max S.
CANCER RESEARCH, 2012, 72
[50] Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy
Park, K
Kim, J
Lim, S
Han, S
EUROPEAN JOURNAL OF CANCER, 2003, 39 (05) : 631 - 634

← 1 2 3 4 5 →